#### Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

**REGENERON PHARMACEUTICALS INC** Form 4 December 18, 2014 OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... 0.5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person \* 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading YANCOPOULOS GEORGE Issuer Symbol REGENERON (Check all applicable) PHARMACEUTICALS INC [REGN] \_X\_ Director 10% Owner X\_Officer (give title Other (specify (Last) (First) (Middle) 3. Date of Earliest Transaction below) below) (Month/Day/Year) President Regeneron Laboratori 777 OLD SAW MILL RIVER 12/16/2014 ROAD (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) \_X\_ Form filed by One Reporting Person Form filed by More than One Reporting TARRYTOWN, NY 10591 Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired 5. Amount of 7. Nature of 6. Transaction(A) or Disposed of (D) Indirect Security (Month/Day/Year) Execution Date, if Securities Ownership (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially Form: Direct Beneficial anv (Month/Day/Year) (Instr. 8) Owned (D) or Ownership Following Indirect (I) (Instr. 4) Reported (Instr. 4) (A) Transaction(s) or (Instr. 3 and 4) V (D) Price Code Amount Common 08/28/2014 V 294 D \$0 D G 500,000 Stock Common \$ 12/16/2014 3.264 Α 503,264 D Μ 30.63 Stock Common 12/16/2014 V 3.264 \$0 D G D 500,000 Stock Common 08/28/2014 V 294 \$0 G Α 568,637 Ι by Trust Stock 11/14/2014 V 2,313 D \$0 566,324 Ι by Trust G

### Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common Stock								
Common Stock	12/16/2014	G	V 3,264	A	\$ 0	569,588	Ι	by Trust
Common Stock						5,623	Ι	By 401(k) Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number orDerivative Securities A (A) or Disp (D) (Instr. 3, 4,	Acquired osed of	6. Date Exer Expiration D (Month/Day,	ate	7. Title and A Underlying S (Instr. 3 and 4
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title
Incentive Stock Option (right to buy)	\$ 30.63	12/16/2014		М		3,264	<u>(1)</u>	12/14/2020	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 52.03	12/16/2014		А	240,000		(2)	12/16/2021	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 399.66	12/16/2014		А	172,723		(3)	12/16/2024	Common Stock

### **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships						
	Director	10% Owner	Officer	Other			
YANCOPOULOS GEORGE 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591	Х		President Regeneron Laboratori				

### Signatures

/s/**George D.	12/18/2014
Yancopoulos	12/10/2014

#### Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

On December 16, 2011, the reporting person was granted an option to purchase 240,000 shares of Common Stock. The option vests, partially or in full, on December 31, 2014, based on the extent to which the company satisfies certain performance criteria during the

- (2) partially of in full, on December 31, 2014, based on the extent to which the company satisfies certain performance effectia during the period ending December 31, 2014. The performance criteria have been met and the option will vest as to all 240,000 shares on December 31, 2014.
- (3) The stock option award vests in four equal annual installments, commencing one year after the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.